EOLS Q3 2022 Earnings — Evolus, Inc. Revenue & Financial Results | Market Cap Arena

EOLSEvolus, Inc.

$353M

Q3 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$34M+27.1% YoY

Gross Profit

$20M60.2% margin

Operating Income

-$18M-52.8% margin

Net Income

-$20M-59.8% margin

EPS (Diluted)

$-0.36

QoQ Revenue Growth

-8.8%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$18M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$193M

Total Liabilities

$163M

Stockholders' Equity

$29M

Cash & Equivalents

$66M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$34M	$27M	+27.1%
Gross Profit	$20M	$15M	+34.4%
Operating Income	-$18M	-$19M	+6.3%
Net Income	-$20M	-$19M	-4.3%

Revenue Segments

Product

$33M98%

Service

$684,0002%